公司前景:
看好 EyePoint 公司的产品 EYP-1901,认为其在可持续释放领域的独特方法(通过眼底注射)构建了一个涉及多个适应症的产品管线。
阐述了 EyePoint 在湿...查看全文
大won2023-12-14 18:13
回复@xiaomzho: 一邊賣EYEPOINT, 一邊囘購。這是上策。//@xiaomzho:回购开始了, 今天买了1.75万股, 距离1亿港币还差99.99%, 算是好的开始了$欧康维视生物-B(01477)$查看全文
同花顺(300033)金融研究中心5月16日讯,有投资者向贝达药业(300558)提问, 董秘您好,我看到贝达与EyePoint签订了有关EYP-1901的合作协议,想问下这款药物目前处于什么阶段?预计什么时候可以上市?是否会对公司经营产生影响? 公... 网页链接
国金证券05月08日发布研报称,维持贝达药业(300558.SZ,最新价:43.75元)买入评级。评级理由主要包括:1)再度携手Eyepoint,给药系统加持伏罗尼布,新型治疗方案值得期待;2)肺癌布局全面,核心产品市场地位维持,新药快速放量。风险提示... 网页链接
《电鳗快报》韩风/文 5月5日,贝达药业股份有限公司(以下简称“贝达药业”)发布了关于公司与EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT,以下简称“EyePoint”)签订EYP-1901合作协议的公告。公告内容显示,5月 4日,贝达药业与 EyePoint... 网页链接
5月5日,贝达药业发布公告,其与EyePoint Pharmaceuticals, Inc. ( 以下简称“EyePoint”)签署《扩大许可协议》,就EYP-1901在中国(包括香港、澳门和台湾)区域的开发和商业化进行独家合作。 根据《扩大许可协议》,贝达药业取得在中国(包... 网页链接
欧康维视生物-B(01477.HK)表示,公司从EyePoint公司授权引进的OT-401(YUTIQ,氟轻松玻璃体内植入剂)新药申请近日已获国家药品监督管理局受理,该药物亦为首款在中国内地提交新药申请的缓释微型植入剂,其在长达36个月内拥有经... 网页链接
格隆汇 1 月 4日丨 欧康维视生物-B(01477.HK)发布公告,2020年12月31日,公司与EyePoint(公司的许可方伙伴之一,其普通股股份以股份代号“EYPT”于纳斯达克交易)订立股份购买协议,据此,EyePoint已同意发行及出售,而公司已同意根据股份购买协议的条款及... 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ 8-K - Current report Filed: 2018-11-06 AccNo: 0001193125-18-318982 Size: 95 KBItem 2.02: Results of Operations and Financial ConditionItem 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 9.01: Financial...
$EyePoint Pharmaceuticals, Inc.(EYPT)$ EFFECT - Notice of Effectiveness Filed: 2018-11-01 AccNo: 9999999995-18-002780 Size: 1 KB 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ S-3/A [Amend] - Registration statement under Securities Act of 1933 Filed: 2018-10-31 AccNo: 0001193125-18-314121 Size: 197 KB 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ 8-K - Current report Filed: 2018-10-31 AccNo: 0001193125-18-313883 Size: 41 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersIte...
$EyePoint Pharmaceuticals, Inc.(EYPT)$ 美东时间 2018-11-06 盘前 披露财报,预期EPS -0.13 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-10-29 AccNo: 0001193125-18-310644 Size: 569 KB 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ 8-K - Current report Filed: 2018-09-28 AccNo: 0001193125-18-287394 Size: 162 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ S-8 - Securities to be offered to employees in employee benefit plans Filed: 2018-09-25 AccNo: 0001193125-18-282686 Size: 80 KB 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-09-18 AccNo: 0001193125-18-276414 Size: 8 MB 网页链接
$EyePoint Pharmaceuticals, Inc.(EYPT)$ 美东时间 2018-09-12 盘前 披露财报,预期EPS -0.09 网页链接